III期SOLO2试验中肿瘤与血液BRCA突变检测的一致性及肿瘤BRCA双等位基因缺失频率
在III期SOLO2试验的铂敏感复发性卵巢癌患者中,肿瘤与胚系BRCA检测一致性极高(BRCA1m 98%、BRCA2m 100%),支持在卵巢癌中推广肿瘤BRCA检测;铂敏感复发卵巢肿瘤中BRCA双等位基因缺失率接近100%,提示该人群无需常规检测BRCA合子性。
要点
- 肿瘤与胚系BRCA检测一致性极高,BRCA1m为98%、BRCA2m为100%,支持推广肿瘤BRCA检测。
- 胚系BRCA1突变肿瘤100%(n=144)、BRCA2突变肿瘤98%(n=66)存在BRCA双等位基因缺失。
- 铂敏感复发卵巢肿瘤中BRCA双等位基因缺失率接近100%,提示该人群无需常规检测BRCA合子性。
核心结论
- 肿瘤与胚系BRCA检测一致性极高,支持在卵巢癌中更广泛地实施肿瘤BRCA检测。
- 铂敏感复发卵巢肿瘤中BRCA双等位基因缺失率接近100%,提示该人群无需常规检测BRCA合子性,并反映BRCA缺失是肿瘤发生的驱动因素。
研究设计与样本
- III期SOLO2试验(NCT01874353)中,对铂敏感复发性卵巢癌且携带BRCA突变患者的血液和肿瘤样本进行分析。
- 对胚系BRCA突变状态(BRACAnalysis® CLIA检测)与肿瘤BRCA突变状态(myChoice® CDx检测)进行一致性分析(Myriad Genetic Laboratories, Inc.)。
- 同时测定BRCA1和BRCA2双等位基因缺失及基因组不稳定评分(GIS)(myChoice® CDx检测)。
主要发现
- 295例入组患者中289例经中心确认存在胚系BRCA突变,241例肿瘤BRCA突变状态可评估。
- 肿瘤与胚系检测对BRCA1m和BRCA2m的一致性分别为98%和100%,共发现4例不一致。
- 210例肿瘤样本可评估BRCA合子性,胚系BRCA1突变肿瘤100%(n=144)和胚系BRCA2突变肿瘤98%(n=66)存在BRCA双等位基因缺失。
- 1例BRCA2m杂合患者GIS为53,无进展生存911天,截至数据截止时仍在接受奥拉帕利治疗。
临床怎么用
- 作者认为,肿瘤与胚系BRCA检测一致性极高,支持在卵巢癌中更广泛地实施肿瘤BRCA检测。
- 作者认为,铂敏感复发卵巢肿瘤中BRCA双等位基因缺失率接近100%,提示该人群无需常规检测BRCA合子性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Maintenance olaparib provided a progression-free survival benefit in the phase III SOLO2 trial (NCT01874353) in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (BRCAm). However, questions remain regarding tumor versus germline BRCA testing and the impact of heterozygous versus bi-allelic loss of BRCA1 or BRCA2 in the tumor. METHODS: Blood and tumor samples were analyzed. A concordance analysis of germline BRCAm status (BRACAnalysis® CLIA test) and tumor BRCAm status (myChoice® CDx test) was conducted (Myriad Genetic Laboratories, Inc.). Bi-allelic loss of BRCA1 and BRCA2 and a genomic instability score (GIS) (myChoice® CDx test) were also determined. RESULTS: 289 of 295 enrolled patients had a germline BRCAm confirmed centrally and tumor BRCAm status was evaluable in 241 patients. There was 98% and 100% concordance between tumor and germline testing for BRCA1m and BRCA2m, respectively, with discordance found in four cases. Of 210 tumor samples evaluable for BRCA zygosity, 100% of germline BRCA1-mutated tumors (n = 144) and 98% of germline BRCA2-mutated tumors (n = 66) had bi-allelic loss of BRCA. One patient with a heterozygous BRCA2m had a GIS of 53, was progression free for 911 days and remained on olaparib at data cut-off. CONCLUSIONS: Very high concordance was demonstrated between tumor and germline BRCA testing, supporting wider implementation of tumor BRCA testing in ovarian cancer. Near 100% rates of bi-allelic loss of BRCA in platinum-sensitive relapsed ovarian tumors suggest routine testing for BRCA zygosity is not required in this population and reflects BRCA loss being a driver of tumorigenesis.
引用
- Hodgson DR, Brown JS, Dearden SP, et al. Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial. Gynecol Oncol. 2021. PMID: 34742578. doi:10.1016/j.ygyno.2021.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。